380 related articles for article (PubMed ID: 24297888)
1. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
[TBL] [Abstract][Full Text] [Related]
2. Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.
Kumar JS; Wei BR; Madigan JP; Simpson RM; Hall MD; Gottesman MM
Sci Rep; 2016 Feb; 6():20418. PubMed ID: 26853103
[TBL] [Abstract][Full Text] [Related]
3. Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
Eadie LN; Saunders VA; Hughes TP; White DL
Leuk Lymphoma; 2013 Mar; 54(3):569-78. PubMed ID: 22845311
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
5. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Blood-Brain Barrier.
Bakhsheshian J; Wei BR; Hall MD; Simpson RM; Gottesman MM
Methods Mol Biol; 2016; 1461():227-39. PubMed ID: 27424909
[TBL] [Abstract][Full Text] [Related]
7. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
8. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
11. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
12. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.
Zhang Y; Bressler JP; Neal J; Lal B; Bhang HE; Laterra J; Pomper MG
Cancer Res; 2007 Oct; 67(19):9389-97. PubMed ID: 17909048
[TBL] [Abstract][Full Text] [Related]
13. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
14. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
[TBL] [Abstract][Full Text] [Related]
15. The Inhibitor Ko143 Is Not Specific for ABCG2.
Weidner LD; Zoghbi SS; Lu S; Shukla S; Ambudkar SV; Pike VW; Mulder J; Gottesman MM; Innis RB; Hall MD
J Pharmacol Exp Ther; 2015 Sep; 354(3):384-93. PubMed ID: 26148857
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.
Matsson P; Pedersen JM; Norinder U; Bergström CA; Artursson P
Pharm Res; 2009 Aug; 26(8):1816-31. PubMed ID: 19421845
[TBL] [Abstract][Full Text] [Related]
18. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
[TBL] [Abstract][Full Text] [Related]
19. A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.
Strouse JJ; Ivnitski-Steele I; Khawaja HM; Perez D; Ricci J; Yao T; Weiner WS; Schroeder CE; Simpson DS; Maki BE; Li K; Golden JE; Foutz TD; Waller A; Evangelisti AM; Young SM; Chavez SE; Garcia MJ; Ursu O; Bologa CG; Carter MB; Salas VM; Gouveia K; Tegos GP; Oprea TI; Edwards BS; Aubé J; Larson RS; Sklar LA
J Biomol Screen; 2013 Jan; 18(1):26-38. PubMed ID: 22923785
[TBL] [Abstract][Full Text] [Related]
20. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
